Vicarious Surgical Reports First Quarter 2026 Financial Results
Rhea-AI Summary
Vicarious Surgical (OTCQB: RBOT) reported first quarter 2026 results for the period ended March 31, 2026. Total operating expenses were $7.5 million, down 52% year-over-year. R&D was $5.0 million (-46%), G&A $2.1 million (-60%), and sales and marketing $0.3 million (-67%). Net loss was $7.3 million, or $1.03 per share, versus a $15.4 million loss ($2.60 per share) in Q1 2025. The company continues to expect full-year 2026 cash burn of approximately $19 million.
Positive
- Total operating expenses reduced by 52% to $7.5M in Q1 2026
- Research and development spending fell 46% to $5.0M in Q1 2026
- General and administrative costs declined 60% to $2.1M in Q1 2026
Negative
- Net loss remained at $7.3M in Q1 2026 (loss per share $1.03)
- Company expects ~$19M full-year 2026 cash burn, indicating continued cash outflow
News Market Reaction – RBOT
In the Apr 30 session, RBOT declined 9.09%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 09 | Q4/FY25 earnings | Positive | +24.3% | Reported lower operating expenses, narrower losses, and below-guidance 2025 cash burn. |
| Nov 12 | Q3 2025 earnings | Positive | -15.5% | Showed lower operating expenses and improved GAAP net loss with added capital raise. |
| Aug 12 | Q2 2025 earnings | Positive | -24.4% | Reported reduced operating expenses and smaller GAAP net loss versus prior year. |
| May 12 | Q1 2025 earnings | Positive | -10.9% | Highlighted modestly lower operating expenses and progress toward clinical stage. |
| Mar 17 | Q4/FY24 earnings | Positive | -14.8% | Reported lower full-year operating expenses and maintained cash burn guidance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings reports often highlighted reduced operating expenses and narrowing losses, yet 4 of the last 5 earnings events saw negative next-day moves, indicating a pattern of weak price follow-through.
Over the last year, Vicarious Surgical’s earnings updates have consistently focused on cutting operating expenses and lowering cash burn. Events on Mar 17, 2025, May 12, 2025, Aug 12, 2025, Nov 12, 2025, and Mar 9, 2026 all reported sizable GAAP net losses but with improving trends and explicit cash burn guidance. The current Q1 2026 report continues this trajectory with sharply lower operating expenses and a reiterated $19M 2026 cash burn expectation, aligning with the strategic shift toward leaner operations seen in prior periods.
Key Terms
cash burn financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (OTCQB: RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2026.
First Quarter 2026 Financial Results
- Total operating expenses were
$7.5 million in the first quarter of 2026, compared to$15.7 million in the first quarter of 2025, a decrease of52% .
- Research and development expenses in the first quarter of 2026 were
$5.0 million , compared to$9.4 million in the first quarter of 2025, a decrease of46% .
- General and administrative expenses in the first quarter of 2026 were
$2.1 million , compared to$5.3 million in the first quarter of 2025, a decrease of60% .
- Sales and marketing expenses in the first quarter of 2026 were
$0.3 million , compared to$1.0 million in the first quarter of 2025, a decrease of67% .
- Net loss in the first quarter of 2026 was
$7.3 million , or net loss per share of$1.03 . This compares to net loss in the first quarter of 2025 of$15.4 million , or net loss per share of$2.60 .
Full Year 2026 Cash Burn Guidance
- Vicarious Surgical continues to expect full year 2026 cash burn of approximately
$19 million .
About Vicarious Surgical
Founded in 2014, Vicarious Surgical is a next-generation surgical robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and has received backing by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.
In accordance with guidance provided by the SEC regarding use by a company of its websites and social media channels as a means to disclose material information to investors and to comply with its disclosure obligations under Regulation FD, the Company hereby notifies investors, the media and other interested parties that it intends to continue to use its investor relations website (https://investor.vicarioussurgical.com/), its LinkedIn page (https://linkedin.com/company/vicarious-surgical/) and its X feed (@VicariousSurg) to publish important information about the Company, including information that may be deemed material to investors. The list of social media channels that the Company uses may be updated on its investor relations website from time to time. The Company encourages investors, the media, and other interested parties to review the information the Company posts on its website and social media channels as described above, in addition to information announced by the Company through its SEC filings, press releases and public conference calls and webcasts.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, including without limitation, statements regarding expectations for cash burn during 2026 and the potential for the Company’s technology to improve patient outcomes, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the effects of quotation of the Class A common stock to quotation on the OTC markets; the Company’s ability to uplist to Nasdaq or another national securities exchange; the approval, commercialization and adoption of the Company’s initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product and service development activities; the potential attributes and benefits of the Company’s product candidates and services; the Company’s ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing license, manufacture, supply and distribution agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; economic downturns, political and market conditions and their potential to adversely affect the Company’s business, financial condition and results of operations; the Company’s intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in the Company’s filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Investor Contact
ir@vicarioussurgical.com
Media Inquiries
media@vicarioussurgical.com
| VICARIOUS SURGICAL INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 5,039 | $ | 9,415 | ||||
| Sales and marketing | 343 | 1,041 | ||||||
| General and administrative | 2,120 | 5,291 | ||||||
| Total operating expenses | 7,502 | 15,747 | ||||||
| Loss from operations | (7,502 | ) | (15,747 | ) | ||||
| Other income (expense), net: | ||||||||
| Change in fair value of warrant liabilities | — | (93 | ) | |||||
| Gain on sale of equipment | 133 | — | ||||||
| Interest and other income, net | 40 | 446 | ||||||
| Total other income, net | 173 | 353 | ||||||
| Net loss | $ | (7,329 | ) | $ | (15,394 | ) | ||
| Net loss per share of Class A and Class B common stock, basic and diluted | $ | (1.03 | ) | $ | (2.60 | ) | ||
| Weighted average shares, diluted | 7,120,298 | 5,924,397 | ||||||
| Other comprehensive loss: | ||||||||
| Net unrealized loss on investments | (6 | ) | (32 | ) | ||||
| Other comprehensive loss | (6 | ) | (32 | ) | ||||
| Comprehensive net loss | $ | (7,335 | ) | $ | (15,426 | ) | ||
| VICARIOUS SURGICAL INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) | ||||||||
| March 31, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 1,407 | $ | 2,569 | ||||
| Short-term investments | 2,275 | 7,223 | ||||||
| Prepaid expenses and other current assets | 1,472 | 1,792 | ||||||
| Total current assets | 5,154 | 11,584 | ||||||
| Restricted cash | 679 | 936 | ||||||
| Property and equipment, net | 1,094 | 1,268 | ||||||
| Right-of-use assets | 5,636 | 5,764 | ||||||
| Other long-term assets | 23 | 29 | ||||||
| Total assets | $ | 12,586 | $ | 19,581 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,030 | $ | 894 | ||||
| Accrued expenses | 770 | 1,056 | ||||||
| Note payable | 371 | 525 | ||||||
| Lease liabilities, current portion | 1,156 | 1,429 | ||||||
| Other current liabilities | 21 | — | ||||||
| Total current liabilities | 3,348 | 3,904 | ||||||
| Lease liabilities, net of current portion | 5,668 | 5,836 | ||||||
| Total liabilities | 9,016 | 9,740 | ||||||
| Stockholders’ equity: | ||||||||
| Class A Common stock | 15 | 15 | ||||||
| Class B Common stock | 2 | 2 | ||||||
| Additional paid-in capital | 257,001 | 255,937 | ||||||
| Accumulated other comprehensive income | (2 | ) | 4 | |||||
| Accumulated deficit | (253,446 | ) | (246,117 | ) | ||||
| Total stockholders’ equity | 3,570 | 9,841 | ||||||
| Total liabilities and stockholders’ equity | $ | 12,586 | $ | 19,581 | ||||
